Medicine and Dentistry
Patient
100%
Hepatocellular Carcinoma
56%
Therapeutic Procedure
46%
Chronic Hepatitis B
29%
Chronic Hepatitis C
28%
Hepatitis C Virus
27%
Liver Cirrhosis
24%
Antiviral Therapy
20%
Hepatitis B Virus
20%
Antivirus Agent
19%
Inpatient
18%
Combination Therapy
18%
Development
17%
Age
15%
Tenofovir Alafenamide
15%
Incidence
14%
Fibrosis
13%
Chronic Kidney Disease
12%
Ribavirin
11%
Entecavir
11%
Cohort Analysis
10%
Human Immunodeficiency Virus
10%
Hepatitis C
9%
Hepatitis B
9%
Genotype
9%
Diagnosis
9%
Telaprevir
9%
Hazard Ratio
9%
Analysis
9%
Infection
8%
Follow up
8%
Peginterferon
8%
Liver
7%
Hepatitis B Antigen
7%
Tenofovir Disoproxil
7%
Interferon
7%
Person
6%
Viral Clearance
6%
Male
6%
Odds Ratio
6%
Nonalcoholic Fatty Liver
6%
Focused Ion Beam
6%
Predictor
6%
Single Nucleotide Polymorphism
6%
Immune Reconstitution Inflammatory Syndrome
6%
Sofosbuvir
6%
Glomerular Filtration Rate
6%
Serum
5%
Ethnic Disparity
5%
Adverse Event
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Hepatitis C
36%
Liver Cell Carcinoma
34%
Ribavirin
34%
Telaprevir
30%
Liver Cirrhosis
27%
Hepatitis C Virus
24%
Antivirus Agent
21%
Adverse Event
17%
Chronic Hepatitis B
16%
Peginterferon
15%
Fibrosis
14%
Hepatitis B Virus
13%
Infection
12%
Hepatitis C
11%
Sofosbuvir
10%
Interferon
10%
Anemia
9%
Incidence
8%
Entecavir
8%
Simeprevir
7%
Hepatitis B
7%
Virus RNA
7%
Tenofovir Alafenamide
7%
Tenofovir Disoproxil
6%
Interleukin 28B
5%
Hepatitis C Virus Subtype 1b
5%
Proteinase Inhibitor
5%
Thrombocytopenia
5%
Hepatitis C Virus Genotype 1
5%
Relapse
5%
Chronic Kidney Failure
5%
Deterioration
5%
Cohort Study
5%
Hepatitis B Surface Antigen
5%
Nursing and Health Professions
Patient
44%
Chronic Hepatitis C
18%
Combination Therapy
18%
Ribavirin
16%
Telaprevir
11%
Liver Cirrhosis
10%
Peginterferon
9%
Incidence
7%
Chronic Hepatitis B
7%
Hepatitis C
7%
Interleukin 28B
7%
Sofosbuvir
6%
Procedures
6%
Inpatient
6%
Antivirus Agent
6%
Antiviral Therapy
5%
Tenofovir Alafenamide
5%
Adverse Event
5%
